Posted inGenetics
Organ Chips Move Towards Mainstream Drug Development, with Hurdles Ahead
In April 2025, the U.S. Food and Drug Administration (FDA) released a strategic roadmap to make animal testing the exception…
Posted inGenetics
State of the Diagnostic Industry: Recombinants on the Rise
Discovery of a fragile foundation Four years ago in GEN, Scripps Laboratories predicted that the clinical diagnostic industry was on…
Posted inBiotechnology
Mesutoclax points to possible shift in high-risk MDS and AML
[00:11] Landscape of MDS and AML [03:45] Higher-risk MDS: treatments challenges after Azacitidine failure[ 07:20 ] Why BCL inhibitions in MDS…
Posted inGenetics
Next Generation Biopharma Innovation
Researchers are digging deeper into biology’s complexity. In preclinical research, the traditional in vivo models are simply not enough to…
Posted inBiotechnology
At ASCO 2026, a ‘paradigm shift’ for a rare gut cancer looms
For patients with a rare cancer that arises in the gut wall, standard treatment hasn’t changed in the last 20…
Posted inGenetics
The Confidence Gap: Why Drug Discovery’s Data Explosion Hasn’t Solved Its Billion-Dollar Decision Problem
Laurence Arnold, PhD Head of R&D Pelago Bioscience We’ve never had more data in drug discovery. Yet despite this explosion…
Posted inBiotechnology
Why Execution Excellence Now Defines Biopharma Winners
In today’s life sciences landscape, having the right strategy and science is no longer enough. According to Harry Georgiades, Managing…
Posted inGenetics
Novel Therapeutic Modalities Target the Undruggable
From small molecules and protein therapeutics to gene therapies, biotech industry players have placed their bets on a wide range…
Posted inGenetics
Mass Spectrometry’s Discovery Revolution
Mass spectrometry (MS) has quietly undergone one of the most consequential evolutions in modern drug discovery. Once viewed primarily as…
Posted inGenetics
Macrocyclic Peptide Drugs Unlocked, Membrane Permeability Screened at Scale
Membrane-permeable cyclic peptide that inhibits the intracellular Keap1-Nrf2 protein-protein interaction. [Christian Heinis (EPFL)] Macrocyclic peptides are a promising drug modality that combine the oral convenience…